Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

NCT01928576 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

143

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer
Epigenetic Therapy

Interventions

DRUG: Azacitidine
DRUG: Entinostat
DRUG: Nivolumab
DRUG: CC-486 300

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]